Article Per Year (5 Year)
p-Index From 2019 - 2024
0.23
P-Index
This Author published in this journals
All Journal Bandung Conference Series: Pharmacy
Aisyah Qanitah
Farmasi, Universitas Islam Bandung
Chemistry Medicine & Pharmacology Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Potensi MUC1 sebagai Target Imunoterapi Triple-Negative Breast Cancer (TNBC) Aisyah Qanitah; Dina Mulyanti
Bandung Conference Series: Pharmacy Vol. 2 No. 2 (2022): Bandung Conference Series: Pharmacy
Publisher : UNISBA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (211.771 KB) | DOI: 10.29313/bcsp.v2i2.4311

Abstract

Abstract. Triple-negative breast cancer (TNBC) is a subtype of breast cancer with aggressive growth and high metastatic rate. However, treatment for TNBC is limited because the three main receptors commonly found in breast cancer are estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) are not found in TNBC cases. Therefore, it is necessary to develop therapy for TNBC patients. Various studies have shown that mucin 1 (MUC1) is overexpressed in TNBC cases as a potential target for immunotherapy in the treatment of TNBC. Abstrak. Triple-negative breast cancer (TNBC)/kanker payudara triple-negatif merupakan subtipe kanker payudara dengan pertumbuhan yang agresif dan tingkat metastasis yang tinggi. Namun pengobatan terhadap TNBC terbatas sebab tidak ditemukannya tiga reseptor utama yang umumnya ditemukan pada kanker payudara yakni reseptor estrogen (ER), reseptor progesteron (PR) dan reseptor faktor pertumbuhan epidermal manusia 2 (HER2). Dengan demikian, diperlukan pengembangan terapi untuk pasien TNBC. Berbagai penelitian menunjukkan mucin 1 (MUC1) yang diekspresikan secara berlebihan pada kasus TNBC berpotensi sebagai target imunoterapi dalam pengobatan TNBC.
Co-Authors Dina Mulyanti